Bevespi Aerosphere Coupons & Savings Card – Discount Prices from $453.53
My prescription
Edit
10.7GM of 9-4.8MCG/ACT, Bevespi Aerosphere (1 Inhaler)
Select pharmacy
CVS
$475.52
COUPON PRICE
Albertsons
$453.53
COUPON PRICE
Walmart
$456.47
COUPON PRICE
Walgreens
$467.46
COUPON PRICEBevespi Aerosphere savings card
Show this card to your pharmacistAlbertsons
$453.53
BIN
ID
PCN
GRP
019876
LH45CA0683
CHIPPO
LHX
Powered by
More prescriptions for copd
More prescriptions for copd
Price history for Bevespi Aerosphere
1 Inhaler, 10.7GM of 9-4.8MCG/ACT
Average retail price for Bevespi Aerosphere
Average SaveHealth price for Bevespi Aerosphere
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Bevespi Aerosphere dosage forms
Dosage Quantity Price from Per unit 10.7GM of 9-4.8MCG/ACT 1 Inhaler $453.53 $453.53 10.7GM of 9-4.8MCG/ACT 2 Inhalers $890.73 $445.37 10.7GM of 9-4.8MCG/ACT 3 Inhalers $1,327.93 $442.64
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 10.7GM of 9-4.8MCG/ACT | 1 Inhaler | $453.53 | $453.53 |
| 10.7GM of 9-4.8MCG/ACT | 2 Inhalers | $890.73 | $445.37 |
| 10.7GM of 9-4.8MCG/ACT | 3 Inhalers | $1,327.93 | $442.64 |
Is Bevespi Aerosphere a steroid?
Bevespi Aerosphere is not a steroid. It is a combination inhaler that contains two active ingredients: glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta-agonist (LABA). It is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
What inhaler is comparable to Bevespi?
A comparable inhaler to Bevespi Aerosphere, which contains glycopyrrolate and formoterol, is Anoro Ellipta. Anoro Ellipta contains umeclidinium and vilanterol, which are also a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA), similar to Bevespi. Both are used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). However, it is important for patients to consult with their healthcare provider to determine the most appropriate treatment for their specific condition.
What is a Bevespi inhaler used for?
A Bevespi inhaler is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It helps to improve breathing by relaxing the muscles around the airways in the lungs, making it easier for air to flow in and out. It is not intended for the relief of acute bronchospasm or as a rescue inhaler.
What is the difference between Symbicort and Bevespi?
Symbicort and Bevespi are both inhalers used to manage chronic obstructive pulmonary disease (COPD), but they contain different active ingredients and have slightly different uses.Symbicort contains a combination of budesonide, a corticosteroid, and formoterol, a long-acting beta-agonist (LABA). It is used for both asthma and COPD to help reduce inflammation and relax the muscles in the airways, making breathing easier.Bevespi, on the other hand, contains glycopyrrolate, a long-acting muscarinic antagonist (LAMA), and formoterol, a LABA. It is specifically used for the maintenance treatment of COPD and works by relaxing and opening the airways in the lungs.In summary, the main difference lies in their active ingredients and specific indications, with Symbicort being used for both asthma and COPD, while Bevespi is used solely for COPD.
Is there a generic for Bevespi?
As of the latest information available, there is no generic equivalent for Bevespi Aerosphere. Bevespi is a combination inhaler containing formoterol and glycopyrrolate, used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Patients should consult their healthcare provider for alternatives or updates on generic availability.